Aclarubicin (Aclacinon)
General information
Class/mechanism from NCI Drug Dictionary: An oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. Aclarubicin intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine.
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Patient drug information
No information available.
Also known as
- Code name: MA144-A1
- Generic names: aclacinomycin, aclacinomycin A, aclacinomycin A hydrochloride, aclacinomycin-A, aclarubicin hydrochloride
- Brand names: Aclacin, Aclacinomycine, Aclacinon, Aclaplastin, Jaclacin